Literature DB >> 2846867

The herpes simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or a trans-activator in combination with ICP4 and ICP0.

R E Sekulovich1, K Leary, R M Sandri-Goldin.   

Abstract

The herpes simplex virus type 1 (HSV-1) alpha proteins ICP4, ICP0, and ICP27 are trans-acting proteins which affect HSV-1 gene expression. To investigate potential interactions between these alpha products and to determine the specificity of action of the alpha proteins in combination with each other compared with their activities individually, we performed a series of transient-expression assays. In these assays we used plasmids containing the alpha genes encoding ICP4, ICP0, and ICP27 either singly or in combination as effectors and HSV-1 genes of different kinetic classes and heterologous genes as targets. The HSV-1 targets consisted of promoter-regulatory domains from alpha (ICP0 and ICP27), beta (thymidine kinase and alkaline exonuclease), beta-gamma (glycoprotein D, glycoprotein B, and VP5), and gamma (glycoprotein C) genes, each fused to the chloramphenicol acetyltransferase (CAT) gene. The heterologous target genes consisted of the simian virus 40 early promoter with enhancer and the Rous sarcoma virus long terminal repeat promoter and enhancer each fused to the CAT gene. Target promoter activity was measured by the assay of CAT activity in extracts of transfected cells and by Northern (RNA) blot hybridization of CAT mRNA. The results of these experiments showed that ICP4 activated only HSV-1 target genes, whereas ICP0 activated all of the targets and ICP27 had little effect on any of the targets. ICP4 and ICP0 had a synergistic effect when inducing HSV-1 targets, but they did not have this effect on the heterologous targets pSV2-CAT or pRSV-CAT. In fact, lower levels of CAT activity and CAT mRNA were found in the presence of both effectors than with ICP0 alone. Most interestingly, although the effector plasmid containing the ICP27 gene had little effect on its own, two different and marked effects depending on the target were observed when ICP27 was combined with ICP4 or ICP0 or both. A trans-repression of the induction seen with ICP4 and ICP0 was found when ICP27 was present in the transfections with pSV2-CAT, pRSV-CAT, pICP0-CAT, pICP27-CAT, pTK-CAT, pgD-CAT, pgB-CAT, and pgC-CAT. This resulted in CAT activity levels which were similar to or lower than the basal level of expression of the target genes in the absence of effector plasmids. This trans-repression occurred over a wide range of concentrations of input ICP27 plasmid. In contrast to this repressive effect of ICP27, a trans-activation was seen when ICP4, ICP0, and ICP27 plasmids were combined in transfections with pAE-CAT and pVP5-CAT as targets. This trans-activation also occurred over a 10-fold range of input ICP27 plasmid. These results suggest that ICP27 can facilitate both down

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846867      PMCID: PMC253561     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  90 in total

1.  Characterization of transcription-deficient temperature-sensitive mutants of herpes simplex virus type 1.

Authors:  R J Watson; J B Clements
Journal:  Virology       Date:  1978-12       Impact factor: 3.616

2.  Autoregulation of simian virus 40 gene A by T antigen.

Authors:  S I Reed; G R Stark; J C Alwine
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

3.  Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK.

Authors:  C M Preston
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

4.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

5.  Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175.

Authors:  R A Dixon; P A Schaffer
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

6.  A herpes simplex virus type 1 function continuously required for early and late virus RNA synthesis.

Authors:  R J Watson; J B Clements
Journal:  Nature       Date:  1980-05-29       Impact factor: 49.962

7.  Analysis of single- and double-stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal and acridine orange.

Authors:  G K McMaster; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

8.  Regulation of herpes simplex virus 1 genes: alpha gene sequence requirements for transient induction of indicator genes regulated by beta or late (gamma 2) promoters.

Authors:  P Mavromara-Nazos; S Silver; J Hubenthal-Voss; J L McKnight; B Roizman
Journal:  Virology       Date:  1986-03       Impact factor: 3.616

9.  Cloning of herpes simplex virus type 1 sequences representing the whole genome.

Authors:  A L Goldin; R M Sandri-Goldin; M Levine; J C Glorioso
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

10.  Trans activation of transcription by herpes virus products: requirement for two HSV-1 immediate-early polypeptides for maximum activity.

Authors:  R D Everett
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

View more
  118 in total

1.  Herpes simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated alpha-globin pre-mRNA in infected HeLa cells.

Authors:  P Cheung; K S Ellison; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants.

Authors:  K S Ellison; S A Rice; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Herpes simplex virus ICP27 protein provides viral mRNAs with access to the cellular mRNA export pathway.

Authors:  M D Koffa; J B Clements; E Izaurralde; S Wadd; S A Wilson; I W Mattaj; S Kuersten
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

4.  The regions important for the activator and repressor functions of herpes simplex virus type 1 alpha protein ICP27 map to the C-terminal half of the molecule.

Authors:  M A Hardwicke; P J Vaughan; R E Sekulovich; R O'Conner; R M Sandri-Goldin
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

5.  Functional analysis of Epstein-Barr virus SM protein: identification of amino acids essential for structure, transactivation, splicing inhibition, and virion production.

Authors:  Vivian Ruvolo; Liang Sun; Karilynn Howard; Seung Sung; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Sankar Swaminathan
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  ICP27 selectively regulates the cytoplasmic localization of a subset of viral transcripts in herpes simplex virus type 1-infected cells.

Authors:  Angela Pearson; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA.

Authors:  W Z Cai; P A Schaffer
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  The influence of the herpes simplex virus-1 DNA template environment on the regulation of gene expression.

Authors:  K Leary; H H Yim; L B Zhou; R E Sekulovich; R M Sandri-Goldin
Journal:  Virus Genes       Date:  1989-09       Impact factor: 2.332

9.  Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA.

Authors:  C R Brown; M S Nakamura; J D Mosca; G S Hayward; S E Straus; L P Perera
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection.

Authors:  M A Hardwicke; R M Sandri-Goldin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.